Zeria Pharmaceutical said on March 27 that it has acquired exclusive rights to develop and commercialize Veltassa (patiromer), a treatment for hyperkalemia, in Japan from Swiss drug maker Vifor Pharma. No financial details were disclosed. A non-absorbed, cation exchange polymer,…
To read the full story
Related Article
- Zeria’s Hyperkalemia Drug Veltassa Now Available in Japan
March 17, 2025
BUSINESS
- Sumitomo to Launch Post-Marketing Study for iPSC Therapy by Year-End
March 9, 2026
- Drug Pricing Reform Draws Sharp Industry Backlash in Jiho Poll
March 9, 2026
- Nitrosamine Detected in Nichi-Iko’s Tryptanol, No Need to Halt Prescriptions
March 9, 2026
- Pfizer, ASKA to Co-Promote RSV Vaccine Abrysvo in Japan
March 9, 2026
- Towa Broadens Label for Tacrolimus in Cell Transplantation
March 9, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





